{
    "root": "d6b874c5-c383-4b28-8be1-2098e4d4fd0a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250520",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "METHACRYLIC ACID",
            "code": "1CS02G8656",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": {
        "text": "divalproex sodium delayed-release capsules anti-epileptic indicated : \u2022 monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 divalproex sodium delayed-release capsules may swallowed whole contents may sprinkled soft food . drug/food mixture swallowed immediately ( avoid chewing ) ( 2.2 ) \u2022 safety doses 60 mg/kg/day established ( 2.1 , 2.2 ) \u2022 complex partial seizures : start 10 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day achieve optimal response ; response satisfactory , check valproate plasma level ; full prescribing information conversion monotherapy ( 2.1 ) \u2022 absence seizures : start 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day seizure control limiting side effects ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "divalproex sodium delayed-release capsules , usp equivalent 125 mg valproic acid white off-white free flowing pellets filled size ' 0 ' hard gelatin capsules blue colored cap printed `` za66 `` black ink white body printed `` 125mg `` black ink supplied follows : overbagged 10 delayed-release capsules per bag , ndc 55154-4759-0 warning : unit dose package child resistant intended institutional . keep drugs reach children . storage : store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . protection : blister torn broken .",
    "adverseReactions": "\u2022divalproex sodium delayed-release capsules administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . \u2022divalproex sodium delayed-release capsules contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . \u2022divalproex sodium delayed-release capsules contraindicated patients known hypersensitivity [ ( 5.12 ) ] . \u2022divalproex sodium delayed-release capsules contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . \u2022for prophylaxis migraine headaches : divalproex sodium delayed-release capsules contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Divalproex sodium delayed-release capsules are an anti-epileptic drug indicated for: \u2022 Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1)",
    "contraindications_original": "\u2022 Divalproex sodium delayed-release capsules may be swallowed whole or the contents may be sprinkled on soft food. The drug/food mixture should be swallowed immediately (avoid chewing) (2.2) \u2022 Safety of doses above 60 mg/kg/day is not established (2.1 , 2.2) \u2022 Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy (2.1) \u2022 Absence Seizures: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects (2.1)",
    "warningsAndPrecautions_original": "Divalproex Sodium Delayed-Release Capsules, USP equivalent to 125 mg of valproic acid are white to off-white free flowing pellets filled in size '0' hard gelatin capsules with blue colored cap printed with \"ZA66\" in black ink and white body printed with \"125mg\" in black ink and are supplied as follows:   \n                  Overbagged with 10 delayed-release capsules per bag,\u00a0NDC 55154-4759-0\n                  WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                  \n                     Storage:\n                      Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [See USP Controlled Room Temperature].  \n                  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.",
    "adverseReactions_original": "\u2022Divalproex sodium delayed-release capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction     [see      Warnings and Precautions (5.1)].     \n                     \n                     \n                        \u2022Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder     [see      Warnings and Precautions (5.1)].     \n                     \n                     \n                        \u2022Divalproex sodium delayed-release capsules are contraindicated in patients with known hypersensitivity to the drug     [see      Warnings and Precautions (5.12)].     \n                     \n                     \n                        \u2022Divalproex sodium delayed-release capsules are contraindicated in patients with known urea cycle disorders     [see      Warnings and Precautions (5.6)].     \n                     \n                     \n                        \u2022For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release capsules are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception     [see      Warnings and Precautions (5.2,      5.3,      5.4) and      Use in Specific Populations (8.1)].",
    "drug": [
        {
            "name": "Divalproex Sodium"
        }
    ]
}